Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7886.043 | 0.4264 | -0.4180 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7886.043 | 0.5155 | -0.2339 | 0.6905 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7892.043 | 1.0359 | 1.0274 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7892.043 | 1.0068 | 1.0053 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7892.043 | 0.9335 | 0.9476 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7892.043 | 1.0674 | 1.0509 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7892.043 | 0.9508 | 0.9615 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7892.043 | 0.8528 | 0.8809 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7892.043 | 0.5461 | 0.5841 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7892.043 | 0.0581 | -0.3323 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7892.043 | 0.3781 | 0.3748 | 2.5944 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7893.007 | 1.1350 | 1.1136 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7893.007 | 1.0765 | 1.0654 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7893.007 | 1.0748 | 1.0640 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7893.007 | 0.9033 | 0.9132 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7893.007 | 0.8164 | 0.8305 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7893.007 | 0.3496 | 0.2642 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7893.007 | 0.3219 | 0.2194 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7893.007 | 0.2266 | 0.0461 | 2.2909 | |
| MDA-MB-231 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7893.007 | 0.1561 | -0.1110 | 2.2909 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7505.078 | 0.9754 | 0.9585 | 1.1847 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7505.078 | 1.0272 | 1.0458 | 1.1847 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7505.078 | 1.0221 | 1.0373 | 1.1847 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7505.078 | 1.0067 | 1.0113 | 1.1847 | |
| MDA-MB-361 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7505.078 | 0.9503 | 0.9158 | 1.1847 |